Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Jennifer Robinson Articles

PlayODYSSEY long term

ODYSSEY long term

Low density lipoprotein cholesterol (LDL-C) was reduced by 60% in patients treated an investigational PCSK9 inhibitor, Alirocumab in addition to statin therapy, for about 52 weeks in the ODYSSEY study. The lead investigator, Professor Jennifer Robinson discusses how this was translated into a reduction in…

read more »